Literature DB >> 22513311

Using models to predict the future: what to do when the data run out?

S G Pauker1, F R Goss.   

Abstract

Although clinical trials often provide "best evidence" comparing the effectiveness of alternative management strategies, such evidence can be limited in duration or in the results reported, causing clinicians and policy analysts to wonder "what if?" Models of the clinical prognosis-often spanning patients' lifetimes (the "long haul")-are perhaps weaker evidence, but can help answer questions about the management of individual patients and place that best evidence into the context of clinical reality.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22513311      PMCID: PMC3711094          DOI: 10.1038/clpt.2012.25

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.

Authors:  M Robinson; S Palmer; M Sculpher; Z Philips; L Ginnelly; A Bowens; S Golder; K Alfakih; A Bakhai; C Packham; N Cooper; K Abrams; A Eastwood; A Pearman; M Flather; D Gray; A Hall
Journal:  Health Technol Assess       Date:  2005-07       Impact factor: 4.014

2.  Preference-Based EQ-5D index scores for chronic conditions in the United States.

Authors:  Patrick W Sullivan; Vahram Ghushchyan
Journal:  Med Decis Making       Date:  2006 Jul-Aug       Impact factor: 2.583

3.  Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

Authors:  Jessica L Mega; Tabassome Simon; Jean-Philippe Collet; Jeffrey L Anderson; Elliott M Antman; Kevin Bliden; Christopher P Cannon; Nicolas Danchin; Betti Giusti; Paul Gurbel; Benjamin D Horne; Jean-Sebastian Hulot; Adnan Kastrati; Gilles Montalescot; Franz-Josef Neumann; Lei Shen; Dirk Sibbing; P Gabriel Steg; Dietmar Trenk; Stephen D Wiviott; Marc S Sabatine
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

4.  The toss-up.

Authors:  J P Kassirer; S G Pauker
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

5.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

6.  The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors.

Authors:  D G Fryback; E J Dasbach; R Klein; B E Klein; N Dorn; K Peterson; P A Martin
Journal:  Med Decis Making       Date:  1993 Apr-Jun       Impact factor: 2.583

Review 7.  Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.

Authors:  C Main; S Palmer; S Griffin; L Jones; V Orton; M Sculpher; R Henderson; C Sudlow; N Hawkins; R Riemsma
Journal:  Health Technol Assess       Date:  2004-10       Impact factor: 4.014

8.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.

Authors:  D B Mark; M A Hlatky; R M Califf; C D Naylor; K L Lee; P W Armstrong; G Barbash; H White; M L Simoons; C L Nelson
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

9.  A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.

Authors:  G F Guzauskas; D A Hughes; S M Bradley; D L Veenstra
Journal:  Clin Pharmacol Ther       Date:  2012-03-28       Impact factor: 6.875

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.